Patents by Inventor John Tomesch

John Tomesch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ORGANIC COMPOUNDS
    Publication number: 20180333403
    Abstract: The disclosure relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., diabetes mellitus, chronic kidney disease, acute kidney failure, and reduction of blood glucose levels.
    Type: Application
    Filed: May 22, 2018
    Publication date: November 22, 2018
    Inventors: Peng LI, Youyi PENG, John TOMESCH, Lawrence P. WENNOGLE, Qiang ZHANG
  • Organic compounds
    Patent number: 9944648
    Abstract: The invention provides novel compounds, composition comprising said compounds and methods for inhibiting CK1 as well as methods of treating CK1 related disorders such as Alzheimer's disease comprising administering a therapeutically effective amount of a CK1 inhibitor to a patient in need thereof.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: April 17, 2018
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Qiang Zhang, Youyi Peng, Peng Li, J. David Beard, Lawrence P. Wennogle, John Tomesch
  • Organic compounds
    Patent number: 9708294
    Abstract: The invention relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., small cell lung cancer.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: July 18, 2017
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Youyi Peng, John Tomesch, Lawrence P. Wennogle, Qiang Zhang
  • ORGANIC COMPOUNDS
    Publication number: 20170190703
    Abstract: The invention provides novel compounds, composition comprising said compounds and methods for inhibiting CK1 as well as methods of treating CK1 related disorders such as Alzheimer's disease comprising administering a therapeutically effective amount of a CK1 inhibitor to a patient in need thereof.
    Type: Application
    Filed: January 9, 2015
    Publication date: July 6, 2017
    Applicant: Intra-Cellular Therapies, Inc.
    Inventors: Qiang Zhang, Youyi Peng, Peng Li, J. David Beard, Lawrence P. Wennogle, John Tomesch
  • 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de] quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms
    Patent number: 9586960
    Abstract: The present invention relates to toluenesulfonic acid addition salt crystals of 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3?,4?: 4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone, and methods of using such crystals as 5-hydroxytryptamine 2 receptor agonists and antagonists in treating disorders of the central nervous system.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: March 7, 2017
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: John Tomesch, Lawrence P. Wennogle
  • ORGANIC COMPOUNDS
    Publication number: 20160326179
    Abstract: The invention provides novel compounds, composition comprising said compounds and methods for inhibiting CK1 as well as methods of treating CK1 related disorders such as Alzheimer's disease comprising administering a therapeutically effective amount of a CK1 inhibitor to a patient in need thereof.
    Type: Application
    Filed: January 9, 2015
    Publication date: November 10, 2016
    Applicant: Intra-Cellular Therapies, Inc.
    Inventors: Qiang Zhang, Youyi Peng, Peng Li, J. David Beard, Lawrence P. Wennogle, John Tomesch
  • Organic compounds
    Patent number: 9469625
    Abstract: The invention relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., small cell lung cancer.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: October 18, 2016
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Youyi Peng, John Tomesch, Lawrence P. Wennogle, Qiang Zhang
  • Compounds and methods of prophylaxis and treatment regarding nicotinic receptor antagonists
    Patent number: 9452160
    Abstract: It is an object of the present invention that the novel nicotinic receptor antagonists disclosed herein may be used in a broad array of clinical or medicinal facets. For example, it is a contemplated use of the present invention that the novel nicotinic receptor antagonists be used to inhibit the growth cycle of non-small cell lung cancer cells. Without being bound by theory, it is an object of the present invention that the nicotinic receptor antagonists disclosed herein are believed to possess reversible binding properties. Moreover, the compounds of the present invention are selective for 0.7 nAChR. For example, the compounds of the present invention are not believed to bind to 0.4 (32 nAChR neuromuscular receptors. It is also contemplated that the nicotinic receptor antagonists of the present invention will be used as a counter measure to treat exposure, or potential exposure, to a wide array of potential neurotoxins.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: September 27, 2016
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Youyi Peng, Lawrence P. Wennogle, Qiang Zhang, John Tomesch
  • ORGANIC COMPOUNDS
    Publication number: 20160237061
    Abstract: The invention relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., small cell lung cancer.
    Type: Application
    Filed: January 11, 2016
    Publication date: August 18, 2016
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng LI, Youyi PENG, John TOMESCH, Lawrence P. WENNOGLE, Qiang ZHANG
  • SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SOLID
    Publication number: 20160194325
    Abstract: The present invention relates to toluenesulfonic acid addition salt crystals of specific substituted heterocycle fused gamma-carbolines, the method of making and using such crystals.
    Type: Application
    Filed: November 30, 2015
    Publication date: July 7, 2016
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: John TOMESCH, Lawrence P. WENNOGLE
  • COMPOUNDS AND METHODS OF PROPHYLAXIS AND TREATMENT REGARDING NICOTINIC RECEPTOR ANTAGONISTS
    Publication number: 20160008343
    Abstract: It is an object of the present invention that the novel nicotinic receptor antagonists disclosed herein may be used in a broad array of clinical or medicinal facets. For example, it is a contemplated use of the present invention that the novel nicotinic receptor antagonists be used to inhibit the growth cycle of non-small cell lung cancer cells. Without being bound by theory, it is an object of the present invention that the nicotinic receptor antagonists disclosed herein are believed to possess reversible binding properties. Moreover, the compounds of the present invention are selective for 0.7 nAChR. For example, the compounds of the present invention are not believed to bind to 0.4 (32 nAChR neuromuscular receptors. It is also contemplated that the nicotinic receptor antagonists of the present invention will be used as a counter measure to treat exposure, or potential exposure, to a wide array of potential neurotoxins.
    Type: Application
    Filed: June 17, 2015
    Publication date: January 14, 2016
    Inventors: Youyi PENG, Lawrence P. WENNOGLE, Qiang ZHANG, John TOMESCH
  • 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals
    Patent number: 9199995
    Abstract: The present invention relates to 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone tosylate salt in crystalline and in solid forms, the method of making and using such crystals.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: December 1, 2015
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: John Tomesch, Lawrence P. Wennogle
  • Compounds and methods of prophylaxis and treatment regarding nicotinic receptor antagonists
    Patent number: 9108949
    Abstract: It is an object of the present invention that the novel nicotinic receptor antagonists disclosed herein may be used in a broad array of clinical or medicinal facets. For example, it is a contemplated use of the present invention that the novel nicotinic receptor antagonists be used to inhibit the growth cycle of non-small cell lung cancer cells. Without being bound by theory, it is an object of the present invention that the nicotinic receptor antagonists disclosed herein are believed to possess reversible binding properties. Moreover, the compounds of the present invention are selective for 0.7 nAChR. For example, the compounds of the present invention are not believed to bind to 0.4 (32 nAChR neuromuscular receptors. It is also contemplated that the nicotinic receptor antagonists of the present invention will be used as a counter measure to treat exposure, or potential exposure, to a wide array of potential neurotoxins.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: August 18, 2015
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Youyi Peng, Lawrence P. Wennogle, Qiang Zhang, John Tomesch
  • SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SOLID
    Publication number: 20140323491
    Abstract: The present invention relates to toluenesulfonic acid addition salt crystals of specific substituted heterocycle fused gamma-carbolines, the method of making and using such crystals.
    Type: Application
    Filed: February 11, 2014
    Publication date: October 30, 2014
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: John Tomesch, Lawrence P. Wennogle
  • COMPOUNDS AND METHODS OF PROPHYLAXIS AND TREATMENT REGARDING NICOTINIC RECEPTOR ANTAGONISTS
    Publication number: 20140205595
    Abstract: It is an object of the present invention that the novel nicotinic receptor antagonists disclosed herein may be used in a broad array of clinical or medicinal facets. For example, it is a contemplated use of the present invention that the novel nicotinic receptor antagonists be used to inhibit the growth cycle of non-small cell lung cancer cells. Without being bound by theory, it is an object of the present invention that the nicotinic receptor antagonists disclosed herein are believed to possess reversible binding properties. Moreover, the compounds of the present invention are selective for 0.7 nAChR. For example, the compounds of the present invention are not believed to bind to 0.4 (32 nAChR neuromuscular receptors. It is also contemplated that the nicotinic receptor antagonists of the present invention will be used as a counter measure to treat exposure, or potential exposure, to a wide array of potential neurotoxins.
    Type: Application
    Filed: June 22, 2012
    Publication date: July 24, 2014
    Inventors: Youyi Peng, Lawrence P. Wennogle, Qing Zhang, John Tomesch
  • ORGANIC COMPOUNDS
    Publication number: 20140205596
    Abstract: The invention relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., small cell lung cancer.
    Type: Application
    Filed: June 22, 2012
    Publication date: July 24, 2014
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Youyi Peng, John Tomesch, Lawrence P. Wennogle, Qiang Zhang
  • 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals
    Patent number: 8648077
    Abstract: The present invention relates to toluenesulfonic acid addition salt crystals of 4-((6bR,10aS)-3-Methyl-2,3,6b,9,10,10a-Hexahydro-1H-Pyrido[3?,4?:4,5]Pyrrolo[1,2,3-De]Quinoxalin-8(7H)-yl)-1-(4-Fluorophenyl)-1-Butanone, the method of making and using such crystals.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: February 11, 2014
    Assignee: Intra-Cellular Therapies, Inc.
    Inventors: John Tomesch, Lawrence P. Wennogle
  • SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SOLID
    Publication number: 20110112105
    Abstract: The present invention relates to toluenesulfonic acid addition salt crystals of specific substituted heterocycle fused gamma-carbolines, the method of making and using such crystals.
    Type: Application
    Filed: March 12, 2009
    Publication date: May 12, 2011
    Inventors: John Tomesch, Lawrence P. Wennogle
  • 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms
    Patent number: RE48825
    Abstract: The present invention relates to toluenesulfonic acid addition salt crystals of 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3?,4?: 4,5]pyrrolo[1,2,3 -de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone, and methods of using such crystals as 5-hydroxytryptamine 2 receptor agonists and antagonists in treating disorders of the central nervous system.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: November 23, 2021
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: John Tomesch, Lawrence P. Wennogle